Aquestive Therapeutics (AQST) Change in Account Payables (2020 - 2026)

Aquestive Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at -$18.0 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 1043.46% year-over-year to -$18.0 million; the TTM figure through Mar 2026 stood at -$355000.0 (down 110.43% YoY), while the FY2025 annual figure was $19.5 million, up 601.76% from the prior year.
• Change in Account Payables was -$18.0 million for Q1 2026 at Aquestive Therapeutics, down from $19.2 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $19.2 million in Q4 2025 to a low of -$18.0 million in Q1 2026.
• Historically, Change in Account Payables has averaged $290882.4 across 5 years, with a median of $182000.0 in 2022.
• The sharpest annual moves came in 2023 and 2026: Change in Account Payables soared 1270.33% in 2023, then slumped 1043.46% in 2026.
• A 5-year view of Change in Account Payables shows it stood at -$1.1 million in 2022, then gained by 5.07% to -$1.1 million in 2023, then surged by 346.82% to $2.6 million in 2024, then jumped by 630.16% to $19.2 million in 2025, then tumbled by 193.38% to -$18.0 million in 2026.
• The last three Change in Account Payables figures came in at -$18.0 million (Q1 2026), $19.2 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.